-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 27th, Quanhecheng announced that it has received nearly 100 million yuan in Series A financing.
This round of financing is led by Tianchuang Capital and Bozheng Capital is cooperating.
The funds raised in this round of financing will be mainly used for the construction and construction of the company's production base.
The research and development of new products, while consolidating the small molecule innovative drug CDMO business, further accelerates the conversion of the core raw material business in the IVD field
.
According to the data, Quanhecheng is a company mainly engaged in the research and development, production, process development, process optimization and other technical services of pharmaceutical intermediates and biological fluorescent probes
.
Quanhecheng’s early business was engaged in CRO services, and later gradually expanded to CDMO business, and its output value also increased from 0 to 100 million yuan
.
In recent years, the domestic small molecule CDMO industry has developed rapidly, and the market scale has continued to expand, far exceeding that of large molecule CDMO
.
According to data from China Industry Information Network, in 2019, the domestic small molecule CDMO market reached 43.
7 billion yuan, with a growth rate of 18%
.
According to F&S calculations, the market size of China's CDMO industry will grow to 104.
88 billion yuan by 2024, and the corresponding growth rate from 2019 to 2024 will reach 26.
5%
.
The agency predicts that the compound annual growth rate of China's small molecule CDMO market from 2018 to 2023 will be 20.
7%
.
In the face of the vast blue ocean of the market, the number of companies entering the market is also increasing.
Relatively speaking, the top companies with rich experience are expected to get opportunities
.
It is reported that in the relatively fiercely competitive small molecule CDMO field, the company has become a core supplier of many leading pharmaceutical companies relying on years of experience in chemical synthesis and production amplification
.
Since 2020, the international market's demand for related drugs, vaccine research and development proteins, and diagnostic reagent raw materials has grown rapidly, and IVD (in vitro diagnostic) raw material companies have also ushered in development opportunities
.
It is reported that Quanhecheng began to deploy IVD raw materials as early as 2013, and successfully developed a number of key IVD raw materials such as dNTPs and fluorescent probes
.
At present, Quanhecheng has provided as many as 13 types of IVD series core raw material products, and the order conversion is tens of millions.
The company plans to further optimize the synthesis process in the next two years and achieve large-scale mass production next year. .
Subsequently, the company will begin to plan the development of the second-level catalog subdivided products, and at the same time build a production base for IVD raw materials to enhance its competitiveness in the field of IVD raw materials
.
In addition, relying on the company’s years of technology accumulation in chemical synthesis, photochemistry and biological applications, the company is also vigorously expanding the market for small nucleic acid pharmaceutical raw materials and mRNA pharmaceutical raw materials with high technical barriers and high investment.
At present, it is capable of producing small nucleic acids in China.
There are few companies for raw materials, and there are only a few qualified suppliers in the field of nucleoside monomers, phosphoramidite monomers, dNTPs and other key nucleic acid drug raw materials
.
The company has broken through key technical difficulties in the research and development of a number of small nucleic acid pharmaceutical raw materials, and is expected to achieve commercialization within the next year
.
It is reported that the follow-up Quanhecheng will focus on key technological achievements for large-scale production, create market-leading products, and provide one-stop services from R&D to production
.
And establish the brand of Quanhecheng, realize early intervention and deep binding of innovative medicine projects, take key core technologies in their own hands, and make continuous efforts for the rapid and stable development of biomedicine
.
With this financing, the company will build a brand-new production base to meet the needs of the fast-growing business in the future
.
This round of financing is led by Tianchuang Capital and Bozheng Capital is cooperating.
The funds raised in this round of financing will be mainly used for the construction and construction of the company's production base.
The research and development of new products, while consolidating the small molecule innovative drug CDMO business, further accelerates the conversion of the core raw material business in the IVD field
.
According to the data, Quanhecheng is a company mainly engaged in the research and development, production, process development, process optimization and other technical services of pharmaceutical intermediates and biological fluorescent probes
.
Quanhecheng’s early business was engaged in CRO services, and later gradually expanded to CDMO business, and its output value also increased from 0 to 100 million yuan
.
In recent years, the domestic small molecule CDMO industry has developed rapidly, and the market scale has continued to expand, far exceeding that of large molecule CDMO
.
According to data from China Industry Information Network, in 2019, the domestic small molecule CDMO market reached 43.
7 billion yuan, with a growth rate of 18%
.
According to F&S calculations, the market size of China's CDMO industry will grow to 104.
88 billion yuan by 2024, and the corresponding growth rate from 2019 to 2024 will reach 26.
5%
.
The agency predicts that the compound annual growth rate of China's small molecule CDMO market from 2018 to 2023 will be 20.
7%
.
In the face of the vast blue ocean of the market, the number of companies entering the market is also increasing.
Relatively speaking, the top companies with rich experience are expected to get opportunities
.
It is reported that in the relatively fiercely competitive small molecule CDMO field, the company has become a core supplier of many leading pharmaceutical companies relying on years of experience in chemical synthesis and production amplification
.
Since 2020, the international market's demand for related drugs, vaccine research and development proteins, and diagnostic reagent raw materials has grown rapidly, and IVD (in vitro diagnostic) raw material companies have also ushered in development opportunities
.
It is reported that Quanhecheng began to deploy IVD raw materials as early as 2013, and successfully developed a number of key IVD raw materials such as dNTPs and fluorescent probes
.
At present, Quanhecheng has provided as many as 13 types of IVD series core raw material products, and the order conversion is tens of millions.
The company plans to further optimize the synthesis process in the next two years and achieve large-scale mass production next year. .
Subsequently, the company will begin to plan the development of the second-level catalog subdivided products, and at the same time build a production base for IVD raw materials to enhance its competitiveness in the field of IVD raw materials
.
In addition, relying on the company’s years of technology accumulation in chemical synthesis, photochemistry and biological applications, the company is also vigorously expanding the market for small nucleic acid pharmaceutical raw materials and mRNA pharmaceutical raw materials with high technical barriers and high investment.
At present, it is capable of producing small nucleic acids in China.
There are few companies for raw materials, and there are only a few qualified suppliers in the field of nucleoside monomers, phosphoramidite monomers, dNTPs and other key nucleic acid drug raw materials
.
The company has broken through key technical difficulties in the research and development of a number of small nucleic acid pharmaceutical raw materials, and is expected to achieve commercialization within the next year
.
It is reported that the follow-up Quanhecheng will focus on key technological achievements for large-scale production, create market-leading products, and provide one-stop services from R&D to production
.
And establish the brand of Quanhecheng, realize early intervention and deep binding of innovative medicine projects, take key core technologies in their own hands, and make continuous efforts for the rapid and stable development of biomedicine
.
With this financing, the company will build a brand-new production base to meet the needs of the fast-growing business in the future
.
